Cargando…
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection. TAF has been shown to be a potent inhibitor of HBV replication at a low dose, with high intracellular concentration and more than 90% lower systemic TFV...
Autores principales: | Ogawa, Eiichi, Furusyo, Norihiro, Nguyen, Mindie H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683768/ https://www.ncbi.nlm.nih.gov/pubmed/29158666 http://dx.doi.org/10.2147/DDDT.S126742 |
Ejemplares similares
-
Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021) -
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
por: Lin, Hung-Yao, et al.
Publicado: (2022) -
Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023) -
Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study
por: Ogawa, Eiichi, et al.
Publicado: (2022) -
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)